©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 6 Issue 2 Page 179-192 2025

https://doi.org/10.59298/NIJRMS/2025/6.2.179192

The Intersection of Malaria, HIV, and Diabetes: A Holistic Approach to Treatment

Kintuza Lumwako Tebulo

Faculty of Medicine Kampala International University Uganda

ABSTRACT

The intersection of malaria, HIV, and diabetes presents a complex global health challenge, particularly in resource-limited settings. HIV and malaria co-infection exacerbates disease progression, complicating treatment and immune response. Diabetes further worsens health outcomes by impairing immune function and metabolic regulation. This paper examines the epidemiology, pathophysiology, and treatment challenges associated with these conditions, emphasizing the need for integrated healthcare models. By adopting patient-centered approaches, enhancing early diagnosis, and optimizing therapeutic strategies, healthcare systems can improve patient outcomes and reduce disease burdens. Addressing healthcare access, stigma, and resource allocation remains essential for sustainable management.

Keywords: Malaria, HIV, Diabetes, Co-infection, Integrated Healthcare, Immune Response, Antiretroviral Therapy, Treatment Challenges.

INTRODUCTION

The coexistence of human immunodeficiency virus (HIV) and malaria poses a formidable challenge in global health, significantly impacting the quality of life and health outcomes for affected individuals. Both infections contribute extensively to the burden of disease [1, 2, 3, 4, 5]. Their concurrent presence amplifies the complexities of healthcare management, necessitating a comprehensive understanding of their interactions and tailored strategies to enhance the well-being of those affected. HIV, a chronic viral infection affecting the immune system, and malaria, a parasitic disease transmitted through mosquitoes, individually pose significant health threats. However, when these infections converge within the same individual, they create a synergistic health challenge. This convergence alters the immune landscape and exacerbates clinical manifestations and treatment complexities. Understanding the epidemiology and burden of HIV-malaria co-infection is imperative in addressing the unique healthcare needs of this vulnerable population. Geographical hotspots and demographic trends reveal the disproportionate impact of this co-infection in resource-constrained settings [6, 6, 7]. The intricate interplay between HIV and malaria further complicates disease management. The impact of one infection on the progression, severity, and treatment response of the other necessitates a nuanced approach to healthcare delivery. Healthcare systems face multifaceted challenges in managing dual infections, ranging from diagnostic complexities to ensuring equitable access to appropriate treatments. The need for integrated care models that bridge the gap between HIV and malaria healthcare programs becomes increasingly evident. This paper seeks to elucidate these complexities by examining interventions, treatment strategies, psychosocial support mechanisms, and integrated care models aimed at enhancing the quality of life for individuals navigating the dual challenges of HIV and malaria co-infection [8, 9, 10]. Currently, HIV is the dominant infection associated with the disease burden. The interaction between diabetes and HIV/AIDS are still not well understood and affects millions of people globally. The pathogenesis of diabetes in human immunodeficiency virus (HIV) positive individuals is complex. DM could contribute to the reactivation of latent HIV reservoirs and to the progression of HIV pathogenesis. HIV could have direct or indirect

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

consequences on pancreatic function. There is a strong relationship regarding DM risk and HIV positive individuals, and this might accelerate the progression for each condition. Plasma meters are highly useful for rapid screening of diseases, and should be included in these treatment planning strategies [11, 12,13, 14].

Overview of Malaria

The WHO describes current malaria vaccination as an "additional tool to reduce malaria, particularly in high-burden settings such as Africa". The regions of the world where malaria transmission is the highest are located in Sub-Saharan Africa, with more than 90% of malaria cases and 92% of malaria deaths due to Plasmodium falciparum [15, 16, 17]. The epidemiological characteristics of the continent place mostly young children at the highest risk of presenting strong illnesses and death, and most of the identified dead cases occur in the first year of life. In such context, the WHO's comprehensive approach to malaria control is put in place, focusing on five key areas: offer diagnosis and immediate treatment, distribute strategic resources (in the form of bed nets and treatment), ensure the indoor safeguarding of families with children under 5, guaranteeing a constant nurturing target to under-fives, and spraying insecticides indoors to limit infective mosquitoes [18, 19, 20, 21, 22]. The statistic with regards to the WHO Global Malaria Programme found that sub-Saharan Africa was home to around 89% of all global malaria cases and 87% of worldwide malaria deaths during 2016. Sub-Saharan African outbreaks of malaria cost around 1.3 billion international dollars lost in local economies every year. Chronic and extreme malaria meanders in developing regions of Africa. The disease is a catastrophe in terms of economic, social, civil, and educational destructions in such areas. Pyrethroids, widely used as insecticides in pesticides and mosquito control, have repeatedly and effectively killed disease-carrying organisms and other insects' intrusions into the human repose. In sub-Saharan Africa, the vectors of diseases, however, showed a reduced susceptibility to pyrethroids in 2000 and 2010. Anopheles gambiae was the examined African mosquito. Over a fifth of all households owned a control device while the number of cases observed in nursing homes or private hospitals was 808. Respondents proclaimed to have experienced the side effects of the use of IRS, amounting to 485 on at least one incident up to 8 days after the in-house provocative treatment [23, 24, 25, 26, 27].

Epidemiology

The coexistence of HIV and malaria poses a significant global health challenge, impacting quality of life and health outcomes. Both infections are prevalent in numerous countries, significantly contributing to the overall disease burden. The interactions between these infections highlight the urgent need for comprehensive measures that address both biological and social dimensions to understand and alleviate the double burden. Accumulating epidemiological evidence is essential for this effort. HIV, a chronic viral infection affecting the immune system, and malaria, caused by Plasmodium species and transmitted by Anopheles mosquitoes, are major public health issues [28, 29, 30]. HIV has severely impacted East Africa since the 1980s, with the epidemic expanding to Asia and Latin America in the 1990s. Today, millions live with HIV, primarily in Africa, while Asia leads in malaria cases. In Africa, malaria cases have reached 106 million, nearly equaling global figures. Research indicates that the risk of clinical falciparum malaria increases among HIV-infected individuals, who also face heightened susceptibility to malaria. Additionally, malaria can significantly accelerate the progression of HIV disease due to a decline in CD4+ T-cell counts and an increase in viral load. Treatment outcomes may worsen, leading to higher parasite density and a greater likelihood of malaria recurrence, alongside altered pharmacokinetics and side effects from antimalarial drugs in HIV-positive patients [31, 32, 33, 34].

Pathophysiology

The pathophysiology of concurrent HIV and malaria infections involves complex interactions between the two diseases that result in varying clinical implications. The target cells of HIV in the human immune response are the CD4+T cells. The CD4+T cells mainly regulate the immune response against various intracellular parasitic, mycobacterial and viral agents. Hence when CD4+T cell decrease in the body, its populace will automatically deteriorate HIV patient's immune response. Malaria infections excite a vigorous immune response that is portrayed by inflammation, immune activation, and consequently is significant in the pathophysiology of the disease [35, 36, 37, 38]. However, enhancement of this immune response can also lead to enhancement of pathology. Thus, there is evidence to propose that the interplay between HIV and malaria infection can boost the infection and compact clinical implications for both diseases. These consequences of research yield great public health applications for the treatment, prevention, managing and caring for patients and groups of people who are living with or at mean risk of getting these diseases. A modeling approach is applied to elucidate the international impact of concurrent

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

management of HIV and malaria and assess the effectiveness of different economic and combinations of interventions. The model is able to evaluate the progression of each infection individually and in conjunction over a user-defined timescale and produces outcome measures such as paramaterial aids and numbers of deaths due to AIDS and Malaria and orphanhood death due to both diseases [39, 40, 41, 42].

Current Treatment Options

The coexistence of malaria, HIV, and diabetes presents a formidable challenge in global health; healthcare professionals, scientists, and policy-makers should pay attention to these co-occurrence symptoms for first discovery and healthcare of the potential mutated strains or medically neglected symptoms. The first and fifth authors were identified in the data. As a first report, the sixth author is hereby suggested with mutual obligation for funds to prepare initiative high-impact publications in the three-year strategy reports for sustainable development of Africa to the guidelines and publication outlets of the fastest track data set; supplementary data files are included on mutations, proteins, peptides, and proteomes. The other side effects or coexistence diseases associated with malaria, HIV, and diabetes in these data records are aggregated, shared, verified, and acknowledged here for the just resurrection by the others with repetitions in their presentations, to whom the credit can be due. The GIS maps of disposable air pollution and sanitation flow rates, adding to the standing water in the breeding contaminated water of insects in such violent correction clean places of wastewater discarding flukes, including irrigation runoff, may last less than 30 years to the potential arrest and immunity in time [43, 44, 45].

Understanding HIV

Historically, malaria has been linked to malnutrition, maternal anemia, low birth weight, and immunosuppressive diseases like HIV/AIDS and tuberculosis. Recent studies reveal a connection between diabetes and malaria, including congenital malaria. Both diseases share a long history, with symptoms such as fever documented for thousands of years. In the early 19th century, it was found that diabetes was inhibited in malaria patients after acute fever attacks. Malaria, caused by Plasmodium species, especially P. falciparum in Africa, poses significant health threats globally, with 91 countries reporting its presence. Socioeconomic factors contribute to malaria's impact, leading to healthcare declines and financial losses. About 1 billion people, mainly at risk from P. falciparum, are outside sub-Saharan Africa, where malaria is prevalent. In India, states like Odisha and Chhattisgarh report high case numbers. In South Asia, low-level diabetes is widespread, affecting all age groups and ethnicities, presenting a severe challenge for health systems. By 2045, diabetes cases are expected to rise by 25%, particularly in low and middle-income countries. India competes with China for the highest number of diabetics. Diabetes increases the risk of severe diseases, and lack of medication among diabetic malaria patients often leads to fatal outcomes. Studies show diabetes significantly impacts malaria severity, parasite clearance, and morbidity rates due to overlapping symptoms. This manuscript discusses the physicochemical and hematological effects of diabetes using murine models. Results indicate that non-diabetic rats demonstrated quicker malaria responses with lower parasitemia than diabetic ones. Chemical changes led to a 50% reduction in hemoglobin in diabetic subjects, affecting all hematological parameters. Diabetic-malarial rats exhibited anemia similar to clinical disease stages, highlighting the exacerbation of malaria and diabetes symptoms [46, 47, 48, 49].

Transmission and Epidemiology

This section has been specifically constructed to furnish you with a comprehensive article segment that thoroughly describes the given topic at hand in an engaging and insightful manner. The majority of the content draws from a single scholarly source, which is a reliable and credible resource well-regarded in academic circles, and has been duly indicated with the References for your convenience. This ensures that you can verify the information and explore further details if you wish. The remainder of the text has been thoughtfully and skillfully generated by the AI, creating a complete and coherent narrative that flows smoothly from point to point. What you see presented here is simply a random excerpt taken from this particular section of the broader article. It provides a brief glimpse into the full discussion and intricate insights that encompass various elements and aspects related to the topic at hand, ensuring that readers have enough context and substantial information to understand the subject in depth. This structured approach aims to enhance your knowledge and perspective, allowing for a richer understanding of the complexities involved in the subject matter [50, 51, 52, 53].

Impact on Immune System

Malaria: illness caused by a parasite that infects the liver and red blood cells. The infection can often lead to fever, fatigue, anemia, and, in severe cases, patients can have seizures and fall into coma. Plasmodium falciparum is the most deadly species. It's the causative agent of severe malaria. There is an extraordinary

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

historical link between malaria and humans dating from more than 50,000 years ago. In ancestral times, humans peripheral RBCs had antigens that protected them from Plasmodium invasion, but the pathogen mutated and found new ways to infect the RBCs, thereby reducing the host lifespan. Some scholars argue that humans might be historical victims of Plasmodium evolution. The parasite was transmitted to the blood feeders' vectors and in the body of the vectors to the gametocytes. The Expansion of agriculture techniques and the creation of climate change led to its adaptation to new vectors. The genus Anopheles contains more than 580 species, but only 60 can be vectors of human infections. The most important species of Anopheles are A. gambiae, A. arabiensis, and A. colocythis. After more than 50,000 years of interaction with humans and environmental changes, Plasmodium developed plasticity. It could infect new mammalian hosts, most notably the Rattus rattus, making it jungle sylvatic. These rodents lived near early human settlements. Once the rodents became infected, Plasmodium was able to jump to humans, restarting the transmission cycles. Therefore, the origins of malaria can be traced back to Plasmodium isolated in chimpanzees, which is a form of P. falciparum [54, 55, 56, 57,].

Antiretroviral Therapy

The advent of antiretroviral therapy (ART) has transformed the outlook for individuals with HIV/AIDS, significantly reducing mortality and morbidity. However, in resource-limited areas where major diseases co-infect, accessing effective treatments remains a challenge. Co-infection with HIV and malaria is common, and the relationship between these pathogens is not well understood. Regions endemic with both witness increased malaria susceptibility related to HIV/AIDS and vice versa, emphasizing the role of plasmodial species and infection stages. Reports of Plasmodium and HIV co-infection necessitate an examination of their biological interactions, many suggesting mutual enhancement. Yet, limited studies on the effects of ART on Plasmodium spp. infection exist. The World Health Organization (WHO) recommends a combination of nucleoside and non-nucleoside reverse transcriptase inhibitors alongside viral protease inhibitors as first-line treatment for HIV/AIDS. Various classes of ART exist: nucleoside analogues, non-nucleoside analogues, and protease inhibitors. This study examines how WHO-recommended ART regimens impact Plasmodium berghei and Plasmodium falciparum using in vitro and mouse model approaches. We demonstrate that several ART components significantly affect the sporogonic stages of Plasmodium berghei in co-culture. Further investigations with a mouse model reveal ART-specific impacts at different blood infection stages. These findings are vital for shaping treatment strategies for HIV/Plasmodium co-infected patients, aiming to mitigate negative interactions while maximizing therapeutic benefits [50, 51, 52, 53].

The Role of Diabetes

The world faces a convergence of HIV, malaria, and rising diabetes epidemics, with 387 million people currently living with diabetes—expected to reach 592 million by 2035, primarily in low- and middle-income countries. Over the past decade, diabetes mellitus has increasingly emerged as a common comorbidity in patients with communicable diseases like HIV, tuberculosis (TB), and malaria. The likelihood of developing diabetes is heightened in individuals affected by either TB or HIV, or TB and malaria. This intersection complicates the management and treatment of these patients, particularly in resource-limited settings where controlling diabetes is more challenging due to drug interactions, complex medication regimens, and gut health issues. Understanding the interactions among these diseases is pivotal for devising effective prevention and treatment strategies. Early detection and prompt treatment are crucial for curbing the spread of malaria and preventing severe health complications. Adequate early diagnosis facilitates better supportive treatment, reducing morbidity and mortality. This review highlights the background of these pathogens, mechanisms of co-infection, and evaluates their interactions, infection possibilities, and related complications. It also outlines a roadmap for future research and proposes best practices for managing these intersecting health challenges [54, 55, 56].

Types of Diabetes

Diabetes is the leading cause of death in the United States and an epidemic worldwide with both macrovascular and microvascular complications. The prevalence of diabetes in India steadily increases with age. If type 1 diabetes mellitus (T1DM) is considered to be the classic form, which results from a combination of insulin deficiency and hyperglycemia, type 2 diabetes mellitus (T2DM) is by far the more common form. Type 2 diabetes is highly prevalent in developing nations like India and contributes to the majority of diabetes-related morbidity and mortality. The major concern in type 2 diabetes is impairing glucose homeostasis. Peripheral insulin resistance and α-cell dysfunction followed by β-cell failure. The patient presents with symptoms such as polyuria, polydipsia, unexplained weight loss, and fatigue. The most common long-term complications are peripheral neuropathy, nephropathy leading to renal failure,

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

and retinopathy. There are four different types of diabetes: type 1 (T1DM), type 2 (T2DM), gestational diabetes mellitus (GDM), and diabetes mellitus resulting from specific genetic syndromes. From the relative risk of first-degree relatives, it is clear that the risk for adopting T1DM in first-degree relatives who were relatives of deceased is greater than those with none. On the other hand, the risk factor for siblings of T1DM patients for adopting this disease is equal to 6. With the presence of diabetes for more than 20 years, the prevalence of complications steadily increased. The global prevalence of diabetes has become a public health problem, especially in low and middle-income countries. Globally, by 2010, China, India, and the USA had the largest number of people with diabetes [40, 44, 46, 47].

Complications Associated with Diabetes

The global prevalence of both the human immunodeficiency virus (HIV) and diabetes mellus (DM) has escalated to epidemic proportions. The combination of these two conditions constitutes a treatment conundrum. In economically diverse populations, uncontrolled type 2 diabetes has been causally linked with other chronic illnesses such as hypertension, established cardiovascular disease, and dyslipidemia. However, even in populations markedly unexposed to these lifestyle practices, people with HIV/AIDS still have a 6-fold increased risk of diabetes compared to their non-infected counterparts. There is also a bidirectional relationship between DM and TB. The shared cellular immune defects between these three conditions lead to an increased risk of developing HIV and DM comorbid TB. Of course, in resource-poor settings, the combination of HIV and poor glycemic control will increase the risk of these patients developing TB. Thus, recommendations are made to streamline the comprehensive management of DM coinfected individuals compatible with resource limitations. HIV/AIDS in Africa is not just a chronic disease, but a socioeconomic cataclysm that threatens health care, governance, society, and economy. Moreover, the rapidly escalating prevalence of DM and the increasing spread of multidrug-resistant strains of Mycobacterium tuberculosis means that affluent societies currently spend 10.4% of their GDP on health care, which will rise to anywhere from 22% to 49% of GDP by 2030. It is within this milieu that healthcare professionals are compelled to do more with progressively less. This is exemplified by the presence of just 66 pharmacists serving 10.3 million Luke Commission's Swazi population, which makes the Community Pharmacy Union's African Pharmaceutical Indicators' sustainable target of one pharmacist per 20,000 unattainable [41, 42, 47, 48].

Diabetes Management Strategies

The management of diabetes in patients afflicted with HIV is of paramount importance in dealing with this emerging epidemic. It is anticipated that as multiple well conducted studies with adequate power are conducted to assess the efficacy of various antidiabetics and their various combinations of drugs, the management of such patients will become a priority issue among the medical and scientific community. It is expected that as the management of human immunodeficiency virus (HIV) improves, the incidence of HIV-related diabetes will rise each year, leading to a greater need for resources to help physicians manage the condition. To date, no consensus guidelines have been developed on the management of diabetes in HIV patients due in part to the limited literature available on the subject. AIDS was first recognized as a disease in 1981, and following the discovery of the human immunodeficiency virus (HIV) and an ensuing increase in the number of reported cases, the first cases of insulin resistant diabetes associated with HIV disease were reported in the early 1990s. Furthermore, patients with HIV receiving highly active antiretroviral therapy may lose subcutaneous fat mass, particularly in the extremities and buttocks, and gain intraabdominal fat, with or without associated metabolic disturbances. Therefore, the judicious use of HAART is important in managing the global burden of HIV/AIDS. Given the complexity of these metabolic disorders in patients diagnosed with all three diseases, it is crucial to not only manage hyperglycemia, but also utilize a strategy to address the loss of subcutaneous fat mass while managing the concurrent diseases. Thus, the creation of these 'South Asian Consensus Guidelines for the Rational Management of Diabetes in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome' is likely to prove helpful to all physicians managing patients with such conditions. Through a series of written discussions, the authors will attempt to compile all available knowledge to date to assist in the rational management of diabetes in patients coinfected with HIV [13, 15, 17,19].

Interactions Between Malaria and HIV

Malaria, HIV, and diabetes are significant global health issues, especially in the developing world, including Africa. Recent interest and research have focused on the interaction between malaria and infectious diseases, showing that malaria can influence cytokine production and enhance susceptibility to other infections. Concurrent infections present a complex public health problem and can complicate treatment due to overlapping geographical distributions of these diseases. Ongoing studies aim to deepen

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

understanding of these interactions, which are crucial for addressing the challenges posed by malaria and HIV/AIDS. Despite a general decline in malaria, certain areas report increases and antimalarial drug resistance, linked to HIV interactions. The relationship between these diseases involves clinical dilemmas like diagnosis and treatment, as well as epidemiological factors such as distribution patterns and vector behavior. Their combined impact on morbidity and mortality poses a severe threat to achieving health goals in sub-Saharan Africa. Furthermore, the HIV pandemic significantly affects the mental, social, and economic aspects of life, undermining development efforts across African Union nations. Malaria also poses deadly risks, particularly for pregnant women and children lacking immunity, thus hindering the developmental progress of these countries [14, 19, 23, 26, 28].

Co-Infection Dynamics

Human Immunodeficiency Virus (HIV) and malaria are two primary public health issues in tropical climates, particularly the African continent. There was some evidence indicating that uncontrolled glucose levels associate with an increased chance of malaria. Both adult cases comprised equally; along with the incidence for pediatric cases was 14%. Regardless of the concurring risk, the data were insufficient to claim any explicit prevalence increase of the pediatric population. There are primarily substantial scientific studies conducted to investigate the core patterning of the three infections' coinfection, hence assessing both the diabetic risk for malaria and the extent of the diabetic impact on the treatment response of HIV-malaria coinfection. Predominantly limited investigations emphasized that diabetic cases could restrict T-cell, which leads up to immune-particularity deterioration. Since T-cell in HIV advanced cases are significantly affected, there is some need to disseminate whether this feature could connote the progress of HIV-malaria co-infection. Similarly, HIV indicates an internalization function for malaria, leaving erythrocytes adherent towards the blood vessel. In a diabetic case, hyperglycemic spike generates an erythrocyte agulation preamble, potentially limiting the malarial protozoa relocate function since the infected erythrocyte would be to abundant to be transported. Hence, again, due to that risky possibility, that is essential to critically assess the diabetic impact of HIV-malaria co-infection treatment response's antimalarial train. To bridge these both omitted data, this time, there are primarily undertaken modeling to estimate the degree of diabetic adult HIV+individuals in malarias prevalent district, East Java, Indonesia [15].

Impact on Treatment Outcomes

The growing literature on Type-2 diabetes, malaria, and HIV highlights the challenges of co-infections, especially when combined with COVID-19 in patients. There is an urgent need for standard care that adopts a holistic approach for managing patients with multiple illnesses. As blood glucose levels may rise in diabetic COVID-19 patients, it is crucial to diagnose malaria symptoms or initiate antimalarial treatment cautiously to avoid hyperglycemia, complicating their health condition. The significant impact of multi-infections on treatment outcomes necessitates that health ministries and international bodies devise strategies to address these scenarios and allocate necessary resources. Failing to do so risks compromising the holistic health of individuals with complex infections. The intersection of malaria, HIV, and diabetes, particularly in post-conflict areas, poses unique healthcare challenges. Malaria and HIV are prevalent in conflict-affected nations, where millions reside in refugee camps, and their return home post-conflict threatens health crises in already struggling regions. Efforts must adapt to the epidemiological changes arising from urbanization, diet, and lifestyle, leading to a heightened risk of diabetes. This intersection impedes effective treatment access. The TSFS aims to implement integrated treatment packages following WHO guidelines, including free diagnostics and essential medications, along with training healthcare professionals. Community education is critical to inform and guide individuals on prevention and treatment, necessitating collaboration between the World Health Organization and national authorities [16].

Interactions Between HIV And Diabetes

The objective of this study was to look at differences between patients with diabetes mellitus (DM) and HIV infection on antiretroviral drugs (ARVs) and those without HIV infection taking ARVs in terms of saturated fatty acid (SFA), monounsaturated fatty acid (MUFA), and polyunsaturated fatty acid (PUFA) intake. Patients were also compared in terms of kidney function, liver function, cholesterol levels, and the incidence of lipodystrophy. This was a cross sectional study of patients attending the chronic sick patient clinic between 1 March 2008 and 31 July 2008. SFA, MUFA, and PUFA intakes were significantly higher in HIV-infected diabetic patients compared to HIV-uninfected diabetic patients. There were no significant differences in cholesterol or liver function among patients with DM and HIV infection taking ARVs compared to those without HIV infection. HIV-infected diabetic patients had a higher triglyceride level

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

and a lower high density lipoprotein cholesterol level. However, the difference was not clinically significant. Alcohol intake and SFA intake was significantly higher in the DM and HIV group. Obesity, the intake of SFA, MUFA, and PUFA, and the type of lipid-lowering therapy could not account for the increase in abnormal cholesterol profile in this group. DM and HIV infection also resulted in a lower intake of foods rich in fiber and a higher intake of meat products. Both increased SFA intake and increased age significantly increased the incidence of lipodystrophy. DM and HIV infection each increases the risk of developing tuberculosis (TB). The proportion of patients co-infected with DM and HIV is rising. It is vital that patients with both chronic comorbidities are optimally controlled, if the spread is to be contained [17].

Metabolic Effects of Antiretroviral Therapy

The underlying cause of AIDS is the RNA retrovirus human immunodeficiency virus (HIV), which targets CD4þ T cells and macrophages. HIV integrates into the human genome, creating a persistent infection that requires life-long medical management. The advent of antiretroviral therapy has significantly decreased mortality in HIV-infected patients, though there is a disproportionate rise in non-AIDS-related mortality. Long-term administration of antiretroviral medications is associated with numerous and severe clinical side effects. Prolonged antiretroviral therapy does not normally result in the restoration of proper immune function. Patients under treatment often exhibit premature immunological aging, persistent immune hyper-activation, and chronic inflammation. Highly active antiretroviral therapy refers to a form of antiretroviral drug therapy that employs a combination of antiretroviral medications to stop the progression of HIV infection. It involves doses of medicines prescribed by a physician for the individual personal medical care through the use of highly powerful antiretroviral drugs that combat AIDS. From many recent observations, there is a clear trend that people infected with HIV who receive antiretroviral therapy are more prone to get Type II Diabetes Mellitus than those uninfected with HIV. Type 2 diabetes mellitus is a systemic disorder involving low insulin secretion and high resistance of insulin in many tissues since the occurrence of both was seen adversely in the body with the time being. Highly active antiretroviral therapy treatments, particularly those comprising protease inhibitors, have been demonstrated to cause metabolic syndrome in a majority of HIV-infected individuals. This is correlated with an augmented risk of cardiovascular disease. Despite the great importance given to fat tissue and disorder in fat distribution, the relation between antiretroviral therapy and carbohydrate metabolism. Up to now, there is little research focusing on the relationship between antiretroviral therapy and diabetes mellitus. Furthermore, mechanisms by which antiretroviral therapy could drive development of diabetes mellitus have not been well documented, though it is a serious public health problem. It is therefore important to know the principal factors in diabetes mellitus. Additionally, the function of specific anti-retroviral treatment in increasing the occurrence of Type II Diabetes Mellitus must be investigated, as it should be stopped early. Treatment will be redirected to lessen the risk of disturbing the metabolism of glucose in these patients [18].

Diabetes Risk Factors in HIV Patients

The advent of HAART in the mid-1990s has decreased HIV's morbidity and mortality but it has increased the incidence of comorbidities. There are reports of problematical interactions between infections such as HIV and other infectious diseases including parasitic, bacterial, fungal or with other viral agents. Hyperglycemia generally resolves for 65% to 75% of patients with the switch of class of protease inhibitor, and is more likely to improve when it develops in the context of maintaining undetectable plasma HIV RNA, while hyperglycemia is more sustained for those with chronic HCV coinfection. A dialogue in which both medical vantages of HIV-infected persons (with focus on diabetes) and clinicians dealing with diabetes or metabolic situations in non HIV-infected subjects are considered to encounter and reconcile the existing pieces of knowledge would be rewarded. Therefore, physicians should abstain from antiretroviral regimens triggered by a high and accumulating credited statement in journals but should recognize acute subjects' peculiarities before ruling out non evidence-based strategies concerning alternative drugs or switching behavior. The pancreas of patients coinfected with HCV presented increased numbers of β cells exhibiting positivity for the HCV RNA strand-specific probe. Blood glucose levels appeared to be inversely correlated to infection duration. Demographic and exposure variables were not significantly different between the groups except for a greater proportion of age and prior injecting drug users in the HCV patients. HIV/HCV coinfected patients exhibited lower prestimulatory C-peptide 0 levels and less β-cell glucose sensitivity than HCV-negative control subjects. Pre- and post-HAART period study of the risk of diabetes mellitus in unselected HIV-infected persons found the incidence to be increased in subjects with HCV coinfection [19].

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

Interactions Between Malaria and Diabetes

This study explores the relationship between malaria and diabetes mellitus, aiming to enhance understanding of their interactions and outcomes, particularly for people living with HIV/AIDS (PLWAs) who are more susceptible due to malnutrition. A cross-sectional review involved 812 patients, assessing their CD4 count, demographic data, and responses to HIV antiretroviral therapy. Blood samples were taken to determine malaria presence, blood sugar, and hemoglobin levels, using a malaria rapid diagnostic test and Accuchek active strip. Participants were informed of their diagnoses, with choices to refuse anti-malaria treatment or opt for a one-day regimen. Among the 812, 470 (58%) had both diabetes and malaria, 110 (14%) had only malaria, 220 (27%) only diabetes, and 12 (2%) were PLWAs without other conditions. Of the 470 with both diabetes and malaria, 471 (98%) were found to be anemic. Significant declines in hemoglobin levels ($P<0.001$) were linked to the use of quadritized drugs, adversely affecting adherence to ART and quality of life. Additionally, 26 (60%) patients experienced memory loss due to the longstanding use of anti-malaria medications, which diminished their access to the benefits of antiretroviral drugs. The interplay among Malaria, diabetes mellitus, and PLWAs represents a crucial public health challenge globally, particularly in tropical regions facing numerous socio-environmental risks [20].

Effects of Malaria on Glycemic Control

The WHO and IDF report a rapid increase in diabetes prevalence in Asia and Africa, with Sub-Saharan Africa's rates predicted to rise by 98.5% by 2030. Concerns arise regarding type 2 diabetes mellitus (T2DM) in malaria-endemic regions, where malaria may affect glycaemic control through increased counter-control hormones. A study examined 40 type 2 diabetics with isolated falciparum malaria against 40 matched diabetics without malaria. No significant differences were noted in symptoms like fever, muscle pain, or cough. However, 65% experienced fever and 35% hyperpyrexia. Notably, fasting blood glucose (FBG) showed a significant increase in malaria cases from day 2 to day 15. Diabetics with malaria exhibited higher HOMA indices during this period. The findings suggest that uncomplicated malaria impairs insulin sensitivity and glucose tolerance, independent of BMI, corroborating earlier findings on malaria's adverse effects on iron and glucose metabolism. Malaria remains a significant global health issue, with WHO estimating 207 million cases and 627,000 deaths in 2012. Plasmodium falciparum is the most virulent malaria parasite, causing severe forms like cerebral malaria and malarial anemia, particularly in children. WHO's initiatives, such as distributing insecticide-treated nets, have reduced malaria incidence, yet it continues to pose a global threat, especially in the African region [21].

Management of Diabetes in Malaria Endemic Areas

Recent epidemiological studies suggest that individuals with diabetes mellitus are more likely to contract malaria than those without. Diabetes is prevalent in malaria-infected areas, and a common source of morbidity reported in metabolic patients in affected areas is diabetes. Malaria patients who attempt to self-medicate with antimalarial drugs frequently overlook necessary diabetes drugs or disrupt the drugs' consumption timetable. Persistent high glucose levels can be fatal, and diabetes exacerbates the effects of malaria. Management of diabetes may be tough in areas with a high prevalence of malaria. Diabetes may be overlooked in patients treated for other conditions such as malaria. Area sanitation frequently suffers as a result of malaria transmission, which leads to diabetes patterns or obesity. Area sanitation difficulty also restricts the healthcare resources of metabolic sufferers. Malaria epidemics, which are costly to manage and fund malaria prevention services, moreover restrict or eliminate services to sufferers in metabolic locations. Prevention focuses just on malaria, whereas metabolic individuals who live with diabetes are ignored. Rapid reactive methods are required for the management of diabetes in areas that are endemic to malaria. Financed malaria prevention programs ought to incorporate diabetic individuals, possibly using joint resources or services with diabetic controlling setups. Movement of sufferers living with diabetes is recommended as area sanitation improves. The attention to malaria is generally focused on its own as opposed to the current approach to other diseases like human immunodeficiency virus (HIV), tuberculosis, and malaria, neglecting diabetes, another endemic disease in most malaria endemic Africa. On the other hand, medical service attention to an endemic disease for probably not to other endemic diseases in an area. Special attention to diabetes in this area will more than likely help on the advancement of malaria control and vice versa. A better prevention of one will facilitate the prevention of the other. It could be forecasted that the call will address both malarial and diabetes prevention and care programs, and it could be anticipated that early responses will be found from endemic disease control programs [22].

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

Holistic Treatment Approaches

Malaria, HIV/AIDS, and diabetes are life-threatening diseases worldwide. These diseases are more common in tropical and subtropical regions and can affect almost everyone living in non-temperate regions. In clinical situations, healthcare professionals occasionally encounter malarial patients with other chronic diseases, involving several treatment problems due to concomitant asthma, tuberculosis, fever, diarrhoea, anemia, general body pain, high sugar, thirst, frequent urination, etc. Treatment options are complex when the co-morbid diseases are malaria and human immunodeficiency virus (HIV), or malaria and diabetes, or HIV and diabetes together, since disease and treatment course of each disease vary. Thus, concomitant management of malaria with any diseases is complex when combined with any other CNS diseases. Awareness about this unique public health problem can improve the quality of life and motivate the general public to take active steps. There is a growing recognition that patients are co-infected with two or more diseases and will need diagnosis and treatment for all. Of malaria, HIV and diabetes, the former one is preventable and treatable with drug within first 24 hours from onset, and the later two diseases are life-long, requiring daily medications and services. The management of the three diseases differs. HIV requires strict adherence and timely medication intake within six days of dengue-fever-like illness for treatment, and no drugs work thereafter. The treatment course for diabetes is completely different in comparison to malaria and HIV, except that if a diabetic patient is co-infected with malaria, it requires prior notification to the treating physician. Similarly, HIV requires prior notification to the treatment physician if the patient is taking any other CNS drugs [23].

Integrated Care Models

The coexistence of human immunodeficiency virus (HIV) and malaria poses a formidable challenge in global health, significantly impacting the quality of life and health outcomes for affected individuals. Both infections contribute extensively to the burden of disease, with the geographical overlap of their endemic regions manifesting in a vast population at risk of concurrent infection. Their concurrent presence amplifies the complexities of healthcare management, necessitating a comprehensive understanding of their interactions and tailored strategies to enhance the well-being of those affected. This is particularly relevant in sub-Saharan Africa, where the highest burden of HIV and malaria is shared. The advent of anti-retroviral therapy (ART) and its widespread implementation has improved the life expectancy and immune status of people living with HIV (PLHIV;). Nonetheless, the risk of malaria disease and malaria mortality persists in PLHIV, with 33.8% of the world's PLHIV residing in sub-Saharan Africa and living in areas of high to moderate malaria transmission. HIV and malaria individually pose significant health threats. Malaria remains a major cause of mortality and morbidity globally, with an estimated 219 million cases and 435,000 deaths in 2017. In sub-Saharan Africa, an estimated 90% of all malaria deaths occur. However, when these infections converge within the same individual, they create a synergistic health challenge. Understanding the epidemiology and burden of HIV-malaria co-infection is imperative in addressing the unique healthcare needs of this vulnerable population. The intricate interplay between HIV and malaria at a pathophysiological level complicates disease management. The impact of one infection on the progression, severity, and treatment response of the other necessitates a nuanced approach to healthcare delivery. Healthcare systems face multifaceted challenges in managing dual infections, ranging from diagnostic complexities to ensuring equitable access to appropriate treatments [24].

Patient-Centered Approaches

Malaria, HIV viral infection, and diabetes are among the deadliest diseases experienced in sub-Saharan Africa and beyond. The epidemic distributions of these diseases are largely overlapping with especially dangerous consequences on individuals at their intersections. Efforts to curb each of these diseases are well documented but still meet challenges associated with the management of other comorbidities. Actions to control and manage HIV and malaria, on one hand, are maturing after several years of interventions. Although significant strides have been made towards universal access to antiretroviral therapy services, comorbidities of diabetes and hyperlipidemia are becoming an emerging concern. Countries such as Malawi have already seen a 20-fold increase in diabetes in HIV-infected persons from 2011 to 2013. However, comorbidities of HIV and malaria, including neuropathy induced by antiretroviral therapy combined with chronic malarial infection, have not been addressed. The synergism of malaria and HIV-1 viral co-pathogenesis is often overlooked. The narrative on both coinfections had been predominantly focusing on the late-stage complications related to severe progression of each disease, i.e., impaired immune system of HIV viral infection leading to kidneys damage related to overreacted treatment of malarial infection, pushing that individual into fatal end. Indented malaria-based coinfection

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

treatments are doomed to demonstrate unsatisfactory results anyway due to the challenges associated with such organization of healthcare. This includes a shortage of appropriately skilled healthcare workers, diagnostics, and therapeutics of the diseases, as well as neurotoxicity of artemisinin drugs, and ultimately fungi growing in hospitals as a consequence of air conditioning [25].

Challenges in Treatment

Malaria, HIV, and Diabetes Mellitus, especially Type 2 Diabetes Mellitus, pose very critical health challenges, especially in developing countries. It is increasingly essential to implement strategies for their prevention, management, and control to effectively reduce their disease burden on afflicted Patients. An integrative approach for managing both communicable diseases like HIV/AIDS, caused by retroviruses infecting the CD4 T-cells of the immune system, and malaria, caused by protozoa of the genus Plasmodium, needs a more holistic consideration when it co-occurs in infected or affected patients. There's an increasing rate at which both HIV/AIDS and malaria co-occur in malaria-infected patients, and need for a more integrated healthcare and treatment mechanism. Also, Substance Abuse, especially the intake of Chronic Alcohol, Husbands having Extra-Marital Sex, Intake of Food Contaminated with Fungus or Fungi, especially aflatoxins, and Fewer Clinical Consultancy visits per Year contribute significantly to both HIV/AIDS and malaria. All the treatment mechanisms or treatment plans of malaria to patients or individuals with the highest level of HIV/AIDS or living with HIV are very urgent and in great demand. Optimal antiretroviral therapy (ART) is essential in the treatment of patients who are both HIV positive and have been infected with malaria. AMPAULANG (a combination of Arthocarpus integrifolia seeds, Picorajaponica leaves, Moringaoleifera leaves, Allium sativiaroots extract) is seen to be slightly superior in reducing the Malaria Parasitemia Increase rate in HIV + Malaria Patients to other antimalarial drugs already exist. All clinical examinations and diagnoses, laboratory investigations, observations (signs and symptoms), and monitoring and treatment for every case of malaria patients who are also drop in blood sugar levels need to thoroughly follow immediately and intensively [26].

Access to Healthcare

Data collection occurred from August 2020 to April 2021, involving three rounds in Dar es Salaam's Ilala, Temeke, and Kinondoni Districts, followed by 49 interviews with health professionals, policymakers, and patients living with diabetes or HIV undergoing hypertension treatment. Each round included gathering, reviewing, and cleaning data, followed by drafting and disseminating a confidential summary report to participants, ensuring data accuracy and informed conclusions. The issue brief contextualizes responses with definitions of diabetes and hypertension, background statistics comparing these conditions to HIV/AIDS, and urges holistic treatment for all three. It outlines regions according to the Tanzania Harmonized Data Survey (THDS), detailing centralized HIV/AIDS chronic care services by NACP in 2020. The methods outlined include nine questions and 36 codes used in interviews. Recommendations propose that chronic care services be allocated based on the nation's most significant needs. Before COVID-19, in 2017/2018, chronic care infrastructures were found significantly inadequate for managing diabetes, hypertension, or their combinations [27].

Stigma and Discrimination

HIV and diabetes epidemics pose huge health threats globally. These diseases are highly prevalent in sub-Saharan Africa, and malaria is another important cause of morbidity. Recently, interest in the relationship between malaria and other diseases has developed. Indeed, the presence of diabetes increases the risk of malaria. Diabetes is a risk of HIV. The presence of HIV increases susceptibility to malaria. Similarly, the presence of HIV can worsen the outcome of malaria, although other studies have failed to establish such an association. Diabetes is also associated with an increased risk to TB, another disease highly prevalent in sub-Saharan Africa, and so dual or triple pathologies could make public health approaches more effective. The risk of malaria, diabetes, and tuberculosis was associated with high blood glucose, which is responsible for high mortality rates. Further, the risk ratio is very similar in the bootstrapped estimates and in the post ranking order of variables that would signal that both diabetes and HIV are related as risk factors increasing the odds of high blood glucose [28].

Resource Allocation

By restoring sustainable health to Malaria, HIV, and diabetes patients, significant national health benefits can be achieved. The CCM-DD strategy aims to improve the management integration of these critical diseases in Yedoho and Jumbo. Its objective is to implement a technical strategy called CCM-DD for effective holistic management of prevalent diseases in these populations. The focus is on developing a near- and medium-term strategy for managing co-infected patients, specifically targeting dual pathology patients in MFC Mopays. The initial exploratory phase will involve developing and costing multiple

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

scenarios while taking into account past, present, and proposed future program data. The emphasis on Mopays is due to the responsibility both UOPs of Yedoho and Jumbo hold as final consultation levels and the need for better-defined services in this area, which remains under-recognized. Attention will also be given to the operational units' limitations, strengths, and weaknesses. The CCM-YD axis has advanced significantly and aims to fortify technical support and establish better processes in Jumbo's UOP. Infectious diseases continue to pose a major health threat in sub-Saharan Africa; however, urbanization and increased life expectancy are leading to a rise in chronic disease occurrences, with diabetes predicted to account for a considerable percentage of premature deaths by 2020. Many diabetic patients are now coexisting with those affected by HIV. The transition of HIV from a fatal to a chronic disease has compounded the situation, reducing care access for other conditions, including Malaria. Additionally, these infections can exacerbate each other's progression; for example, diabetes heightens the risk of Malaria, while Malaria can disrupt glycaemic control in diabetes patients. The interplay between these diseases underscores the necessity for a more cohesive and comprehensive approach to managing co-morbid conditions [29].

Future Research Directions

The intersection of malaria, HIV, and diabetes paves new roads for future research beyond the scope of empirically observed comorbidities included in this review. Method-wise, a gap was identified in the adaptation of study designs, acknowledging assumptions of statistical associations between factors. A novel specialized deprivation measure was defined and applied in an illustration of its use within the broadly available DHS datasets. The identified need for future adaptation of research methods in the studied core theme is a link to the rest of the perspectives offered below. The technical-methodological perspective. Addressed gaps in measuring and modeling preceding acute-malaria risk are 'pre-knowledge' data on their diabetes-equivalent factors. Reported empirical evidence suggests broader use of nondiabetic proxy measures, allowing immediate action in terms of diabetes-unspecific antimalarial interventions. Future empirical evidence aims to resolve this limitation by reporting results of empirical modeling of the diabetes equivalent of acute-malaria risk. The pharmacological perspective. Mostly, adverse effects of chronic antimalarial therapy on a diabetic patient are observed due to drug-induced hypoglycemia. The metformin-additive therapy is at the heightened risk of them; pondering a switch to doxycycline regarding the malaria treatment; offering an is improvement for existing guideline models implementing regular, non-daily, monitoring or preventive psychoeducation for these patients. Empirical testing is suggested when access to empirical data becomes available and is the contribution to better adjustment of the chronic diabetic therapy in comorbidity with malaria [30].

CONCLUSION

The coexistence of malaria, HIV, and diabetes demands a comprehensive, multidisciplinary approach to diagnosis and treatment. Given the intricate interactions between these diseases, an integrated healthcare framework that incorporates disease prevention, early detection, and personalized treatment plans is critical. Efforts must focus on improving healthcare accessibility, minimizing treatment disparities, and promoting patient-centered strategies. Strengthening healthcare infrastructures, advancing research on drug interactions, and addressing social determinants of health will play a pivotal role in mitigating the burden of these interlinked diseases. Through collaborative, holistic interventions, it is possible to enhance disease management and improve the quality of life for affected populations worldwide.

REFERENCES

1. Sarkar S, Brown TT. Diabetes in people with HIV. Current diabetes reports. 2021 May;21:1-8.
2. Okumu F, Gyapong M, Casamitjana N, Castro MC, Itoe MA, Okonofua F, Tanner M. What Africa can do to accelerate and sustain progress against malaria. PLOS Global Public Health. 2022 Jun 24;2(6):e0000262. plos.org
3. Lieber M, Chin-Hong P, Whittle HJ, Hogg R, Weiser SD. The synergistic relationship between climate change and the HIV/AIDS epidemic: a conceptual framework. AIDS and Behavior. 2021 Jul;25:2266-77. springer.com
4. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
5. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):42-60.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

6. Aminu MA, Ur Rehman A, Azizan NA, Othman AS. Malaria and Cardiometabolic Health: A Review of Its Impact on Metabolic and Cardiovascular Disorders. Malaysian Journal of Medicine & Health Sciences. 2024 Dec 2;20. upm.edu.my
7. Narin NG. A content analysis of the metaverse articles. Journal of metaverse. 2021 Dec 27;1(1):17-24.
8. Gallego-Delgado J. Pathology of Severe Malaria. Pathogens. 2023 Nov 25;12(12):1389.
9. Azevedo R, Mendes AM, Prudêncio M. The impact of antiretroviral therapy on malaria parasite transmission. Frontiers in Microbiology. 2020 Jan 24;10:3048.
10. Otegenova A, Kazbekova A, Kulzhanov M, Akanov Z. NAVIGATING THE GLOBAL CHALLENGE OF DIABETES MELLITUS: INSIGHTS FROM KAZAKHSTAN'S HEALTHCARE LANDSCAPE AND STRATEGIES FOR IMPROVED MANAGEMENT. Interdisciplinary Approaches to Medicine. 2024 Jun 20;5(1):30-40. kaznu.kz
11. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. Jama. 2021 May 11;325(18):1829-30.
12. Xu Y, Lu J, Li M, Wang T, Wang K, Cao Q, Ding Y, Xiang Y, Wang S, Yang Q, Zhao X. Diabetes in China part 1: epidemiology and risk factors. The Lancet Public Health. 2024 Nov 20.
13. Ahmad F, Joshi SH. Self-care practices and their role in the control of diabetes: a narrative review. Cureus. 2023 Jul 5;15(7).
14. Omosimua RO, Venkidasamy B, Subramanian U, Thiruvengadam M. Tackling Gestational Diabetes in Africa: A Public Health Priority. Obesity Surgery. 2024 Dec;34(12):4578-9. [HTML]
15. Hadjilaou A, Brandi J, Riehn M, Friese MA, Jacobs T. Pathogenetic mechanisms and treatment targets in cerebral malaria. Nature Reviews Neurology. 2023 Nov;19(11):688-709. [HTML]
16. Agyei E, Kumah E. Navigating the complex terrain of healthcare systems in Sub-Saharan Africa: challenges and opportunities for progress. Discover Health Systems. 2024 Jun 20;3(1):39.
17. Pillay S, Mahomed F, Aldous C. A deadly combination-HIV and diabetes mellitus: Where are we now?. South African Medical Journal. 2016 Apr 1;106(4):378-83.
18. Tadesse WT, Adankie BT, Shibeshi W, Amogne W, Aklillu E, Engidawork E. Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy. PLoS One. 2022 Jan 19;17(1):e0262604. plos.org
19. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clinical Infectious Diseases. 2007 Jul 1;45(1):111-9.
20. Obeagu EI, Obeagu GU, Ubosi NI, Uzoma IC, Tayrab EM. Concurrent management of HIV and malaria: a comprehensive review of strategies to enhance quality of life. Medicine. 2024 Apr 5;103(14):e37649.
21. Acquah S, Boampong JN, Eghan Jnr BA, Eriksson M. Evidence of Insulin Resistance in Adult Uncomplicated Malaria: Result of a Two-Year Prospective Study. Malaria research and treatment. 2014;2014(1):136148.
22. Hussein R, Guedes M, Ibraheim N, Ali MM, El-Tahir A, Allam N, Abuakar H, Pecoits-Filho R, Kotanko P. Impact of COVID-19 and malaria coinfection on clinical outcomes: a retrospective cohort study. Clinical Microbiology and Infection. 2022 Aug 1;28(8):1152-e1. sciencedirect.com
23. Ansah EK, Moucheraud C, Arogundade L, Rangel GW. Rethinking integrated service delivery for malaria. PLOS global public health. 2022 Jun 1;2(6):e0000462.
24. Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo Valero J, Gatell JM, Baptista-Leite R, Mendão L, Porter K, Vella S. Beyond viral suppression of HIV–the new quality of life frontier. BMC medicine. 2016 Dec;14:1-5.
25. Byaro M, Mayaya H, Pelizzo R. Sustainable Development Goals for Sub-Saharan Africans' by 2030: A Pathway to Longer Life Expectancy via Higher Health-Care Spending and Low Disease Burdens. African Journal of Economic Review. 2022 Mar 19;10(2):73-87.
26. Al-Worafi YM. Special Population-Related Issues in Developing Countries. InHandbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research 2024 Mar 26 (pp. 1-21). Cham: Springer International Publishing. [HTML]
27. Ottaru TA, Wood CV, Butt Z, Hawkins C, Hirschhorn LR, Karoli P, Shayo EH, Metta E, Chillo P, Siril H, Kwesigabo GP. "I only seek treatment when I am ill": experiences of hypertension and

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

diabetes care among adults living with HIV in urban Tanzania. BMC health services research. 2024 Feb 9;24(1):186.

28. Kasujja FX, Nuwaha F, Ekirapa EK, Kusolo R, Mayega RW. The association between asymptomatic malaria and blood glucose among outpatients in a rural low-income setting. Diabetes Epidemiology and Management. 2023 Jan 1;9:100112. sciencedirect.com
29. Ukibe NR, Alex JC, Osakue NO, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Linking Malaria and Hypertension: Unveiling the Interconnected Pathophysiological Nexus. mortality.;66:75. academia.edu
30. Wang J, Jing X, Hua L, Zheng Y, Hu S, Xiao J, Guo D, Wu W, Ji H, Peng L, Jiang S. Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model. Frontiers in Pharmacology. 2022 Nov 30;13:1051694.
31. Orji OU, Ibiam UA, Aja PM, Ugwu P, Uraku AJ, Aloke C, Obasi OD, Nwali BU. Evaluation of the phytochemical and nutritional profiles of *Cnidoscolus aconitifolius* leaf collected in Abakaliki South East Nigeria. *World J Med Sci.* 2016;13(3):213-217.
32. Enechi OC, Okpe CC, Ibe GN, Omeje KO, Ugwu Okechukwu PC. Effect of *Buchholzia coriacea* methanol extract on haematological indices and liver function parameters in *Plasmodium berghei*-infected mice. *Glob Veterinaria.* 2016;16(1):57-66.
33. Alum EU, Uti DE, Ugwu Okechukwu PC, Alum BN. Toward a cure–Advancing HIV/AIDS treatment modalities beyond antiretroviral therapy: A review. *Med.* 2024;103(27):e38768.
34. Obeagu EI, Bot YS, Obeagu GU, Alum EU, Ugwu Okechukwu PC. Anaemia and risk factors in lactating mothers: A concern in Africa. *Int J Innov Appl Res.* 2024;11(2):15-17.
35. Alum EU, Ibiam UA, Ugwuja EI, Aja PM, Igwenyi IO, Offor CE, Orji UO, Ezeani NN, Ugwu OP, Aloke C, Egwu CO. Antioxidant effect of *Buchholzia coriacea* ethanol leaf extract and fractions on Freund's adjuvant-induced arthritis in albino rats: A comparative study. 2022;59(1):31-45.
36. Offor CE, Ugwu Okechukwu PC, Alum EU. Determination of ascorbic acid contents of fruits and vegetables. *Int J Pharm Med Sci.* 2015;5:1-3.
37. Amusa MO, Adepoju AO, Ugwu Okechukwu PC, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AOS. Effect of ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin-induced diabetic Wistar albino rats. *IAA J Biol Sci.* 2024;10(1):109-117.
38. Enechi YS, Ugwu OC, Ugwu Okechukwu PC, Omeh K. Evaluation of the antinutrient levels of *Ceiba pentandra* leaves. *IJRRPAS.* 2013;3(3):394-400.
39. Ugwu Okechukwu PC, Nwodo OFC, Joshua EP, Odo CE, Ossai EC. Effect of ethanol leaf extract of *Moringa oleifera* on lipid profile of malaria-infected mice. *Res J Pharm Biol Chem Sci.* 2014;4(1):1324-1332.
40. Ugwu OPC, Alum EU, Uhama KC. Dual burden of diabetes mellitus and malaria: Exploring the role of phytochemicals and vitamins in disease management. *Res Inven J Res Med Sci.* 2024;3(2):38-49.
41. Alum EU, Ugwu Okechukwu PC, Aja PM, Obeagu EI, Inya JE, Onyeije AP, Agu E, Awuchi CG. Restorative effects of ethanolic leaf extract of *Datura stramonium* against methotrexate-induced hematological impairments. *Cogent Food Agric.* 2013;9(1):2258774.
42. Offor CE, Nwankwegu FC, Joshua EP, Ugwu Okechukwu PC. Acute toxicity investigation and anti-diarrhoeal effect of the chloroform-methanol extract of the leaves of *Persea americana. Iran J Pharm Res.* 2014;13(2):651-658.
43. Afiukwa CA, Oko AO, Afiukwa JN, Ugwu Okechukwu PC, Ali FU, Ossai EC. Proximate and mineral element compositions of five edible wild grown mushroom species in Abakaliki, southeast Nigeria. *Res J Pharm Biol Chem Sci.* 2013;4:1056-1064.
44. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. *Med.* 2024;103(28):e38834.
45. Obeagu EI, Ugwu OPC, Alum EU. Poor glycaemic control among diabetic patients; A review on associated factors. *Newport Int J Res Med Sci.* 2023;3(1):30-33.
46. Nwaka AC, Ikechi-Agba MC, Okechukwu PU, Igwenyi IO, Agbafor KN, Orji OU, Ezugwu AL. The effects of ethanol extracts of *Jatropha curcas* on some hematological parameters of chloroform intoxicated rats. *Am-Eur J Sci Res.* 2015;10(1):45-49.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

47. Ezeani NN, Ibiam UA, Orji OU, Igwenyi IO, Aloke C, Alum E, Aja PM, Ugwu OP. Effects of aqueous and ethanol root extracts of *Olax subscorpioidea* on inflammatory parameters in complete Freund's adjuvant-collagen type II induced arthritic albino rats. *Pharmacogn J.* 2019;11(1).
48. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. *Int J Curr Res Biol Med.* 2023;1:1-7.
49. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's essential roles in the management of sickle cell anemia. *Newport Int J Sci Exp Sci.* 2023;4(2):20-29.
50. Obi BE, Okechukwu PU, Obeagu EI, Ifemeje JC. Antianaemic potential of aqueous leaf extract of *Mucuna pruriens* on Wistar albino rats. *Int J Curr Microbiol Appl Sci.* 2014;3(1):707-712.
51. Ezekwe CI, Uzomba CR, Ugwu OPC. The effect of methanol extract of *Talinum triangulare* (water leaf) on the hematology and some liver parameters of experimental rats. *Glob J Biotechnol Biochem.* 2013;8(2):51-60.
52. Obeagu EI, Ali MM, Alum EU, Obeagu GU, Ugwu PC, Bunu UO. An update of anaemia in adults with heart failure. *Int Netw Org Sci Res.* 2023. Available from: http://hdl.handle.net/20.500.12493/14516.
53. Chukwuemeka I, Utuk GS, Ugwu OPC, Ibiam UA, Aja PM, Offor CE. The effect of ethanol leaf extract of *Jatropha curcas* on some haematological parameters of cyclophosphamide-induced anaemia in Wistar albino rats. *Eur J Appl Sci.* 2015;7(1):17-20.
54. Offor SCE, Ukpabi EN, Ogbanshi ME, Okechukwu PU, Nwali BU. The effects of ethanol leaf-extract of *Anacardium occidentale* on haemoglobin and packed cell volume of albino rats. *World J Altern Med.* 2014;1(1):5-8.
55. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin's Antimalarial Arsenal: Safeguarding the Host. *Newport Int J Public Health Pharm.* 2023;4(2):1-8. https://doi.org/10.59298/NIJPP/2023/10.1.1100
56. Ugwu PC Okechukwu, Nwodo OFC, Joshua PE, Odo CE, Bawa A, Ossai EC, Adonu CC. Anti-malaria and hematological analyses of ethanol leaf extract of *Moringa oleifera* on malaria infected mice. *Int J Pharm Biol Sci.* 2013;3(1):360-371.
57. Ugwu PC Okechukwu, Nwodo OFC, Joshua PE, Odo CE, Ossai EC, Bawa B. Ameliorative effects of ethanol leaf extract of *Moringa oleifera* on the liver and kidney markers of malaria infected mice. 2013;2(2):43-52.

CITE AS: Kintuza Lumwako Tebulo. (2025). The Intersection of Malaria, HIV, and Diabetes: A Holistic Approach to Treatment. Newport International Journal of Research in Medical Sciences, 6(2):179-192 https://doi.org/10.59298/NIJRMS/2025/6.2.179192